MSS/ MMRp

我们是谁

  • 4 月 5, 2022
    Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
  • 4 月 5, 2022
    Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
  • 4 月 5, 2022
    A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
  • 4 月 5, 2022
    晚期或转移性实体瘤 NGM831 单药及与 Pembrolizumab 联合用药研究
  • 4 月 5, 2022
    西妥昔单抗和维莫非尼联合 FOLFIRI 治疗 BRAF V600E 突变的晚期结直肠癌 (IMPROVEMENT)
  • 4 月 5, 2022
    Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
  • 4 月 5, 2022
    评估体外下一代新抗原选择的肿瘤浸润淋巴细胞（TIL）疗法在晚期上皮肿瘤和免疫检查点阻断剂（ICB）耐受性实体瘤中的安全性和耐受性
  • 4 月 5, 2022
    iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
  • 4 月 5, 2022
    Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
  • 4 月 5, 2022
    Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer